



1/22/04

~~\$1695~~
1689
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Logtenberg et al.

Serial No.: 09/940,386

Filed: August 27, 2001

For: DIFFERENTIALLY EXPRESSED
EPITOPES AND USES THEREOF

Confirmation No.: 4365

Examiner: T. Wessendorf

Group Art Unit: 1645

Attorney Docket No.: 2578-4514.1US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

February 4, 2004
Date

Betty Vowles
Signature

Betty Vowles
Name (Type/Print)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in

02/11/2004 AKOCHA1 00000022 09940386

01 FC:1806

100.00 OP

37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

Other Documents

ALEXANIAN et al., Drug Therapy, The New England Journal of Medicine, Feb. 17, 1994, pp. 484-89, Vol. 330, No. 7.

ATTAL et al., A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma, The New England Journal of Medicine, July 11, 1996, pp. 91-97, Vol. 335, No. 2.

BASELGA et al., Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, March 1996, pp. 737-744, Vol. 14, No. 3.

BJORKSTRAND et al., Autologous Stem Cell Transplantation in Multiple Myeloma: Results of the European Group for Bone Marrow Transplantation, Stem Cells, 1995, pp. 140-46, Vol. 13.

BOCCADORO et al., Diagnosis, Prognosis, and Standard Treatment of Multiple Myeloma, Hematology/Oncology Clinics of North America, February 1997, pp. 111-31, Vol. 11, No. 1.

BODEY et al., Genetically Engineered Monoclonal Antibodies for Direct Anti-Neoplastic Treatment and Cancer Cell Specific Delivery of Chemotherapeutic Agents, Current Pharmaceutical Design, 2000, pp. 261-76, Vol. 6.

BOEL et al., Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments, Journal of Immunological Methods, 2000, pp. 153-66, Vol. 239.

BRUGGEMANN et al., Strategies for expressing human antibody repertoires in transgenic mice, Immunology Today, August 1996, pp. 391-397, Vol. 17, No. 8.

BURTON et al., Human Antibodies from Combinatorial Libraries, Advances in Immunology, pp. 191-280, Vol. 57.

CUNNINGHAM et al., High-Dose Melphalan and Autologous Bone Marrow Transplantation as Consolidation in Previously Untreated Myeloma, *Journal of Clinical Oncology*, April 1994, pp. 759-63, Vol. 12. No. 4.

CURNOW, Clinical experience with CD64-directed immunotherapy. An overview, *Cancer Immunol Immunother*, pp. 210-15, Vol. 45.

de KRUIF et al., Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library, *Proc. Natl. Acad. Sci.*, April 1995, pp. 3938-42, Vol. 92.

de KRUIF et al., Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions, *J. Mol. Biol.*, 1995, pp. 97-105, Vol. 248.

de KRUIF et al., New perspectives on recombinant human antibodies, *Trends*, October 1996, pp. 453-55, Vol. 17, No. 10.

DENNIS et al., Protein glycosylation in development and disease, *BioEssays*, 1999, pp. 412-21, Vol. 21.

DORIG et al., The Human CD46 Molecule Is a Receptor for Measles Virus (Edmonston Strain), *Cell*, October 22, 1993, pp. 295-305, Vol. 75.

ELLIOTT et al., Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis, *The Lancet*, October 22, 1994, pp. 1125-27, Vol. 344.

ENGELMANN et al., Modulated glycosylation of proteoglycans during differentiation of human B lymphocytes, *Biochimica et Biophysica Acta*, 1995, pp. 6-14, Vol. 1267.

FAROOQ et al., Glycosylation of polyclonal and paraprotein IgG in multiple myeloma, *Glycoconjugate Journal*, 1997, pp. 489-92, Vol. 14.

FOOTE et al., Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops, *J. Mol. Biol.*, 1992, pp. 487-99, Vol. 224.

GRANZIERO et al., Baculovirus cDNA libraries for expression cloning of genes encoding cell-surface antigens, *Journal of Immunological Methods*, 1997, pp. 131-309, Vol. 203.

HAKIMI et al., Reduced Immunogenicity and Improved Pharmacokinetics of Humanized Anti-Tac in Cynomolgus Monkeys, *The Journal of Immunology*, August 15, 1991, pp. 1352-59, Vol. 147, No. 4, USA.

HARA et al., Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma tears, and seminal fluid in normal subjects, *Clin. exp. Immunol.* 1992, pp. 490-94, Vol. 89.

HAROUSSEAU et al., Autologous Stem Cell Transplantation After First Remission Induction Treatment in Multiple Myeloma: A Report of the French Registry on Autologous Transplantation in Multiple Myeloma, *Blood*, June 1, 1995, pp. 3077-85, Vol. 85, No. 11.

HAVENGA et al., Methotrexate selectable retroviral vectors for Gaucher disease, *Gene Therapy*, 1998, pp. 1379-88, Vol. 5.

HULS et al., A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments, *Nature Biotechnology*, March 1999, pp. 276-81, Vol. 17.

IWATA et al., Diversity of Sites for Measles Virus Binding and for Inactivation of Complement C3b and C4b on Membrane Cofactor Protein CD46*, *The Journal of Biological Chemistry*, 1995, pp. 15148-52, Vol. 270, No. 25.

JONES et al., Replacing the complementarity--determining regions in a human antibody with those from a mouse, *Nature*, May 1986, pp. 522-525, Vol. 321.

JUHL et al., Frequent Expression of Complement Resistance Factors CD46, CD55, and CD59 on Gastrointestinal Cancer Cells Limits the Therapeutic Potential of Monoclonal Antibody 17-1A, *Journal of Surgical Oncology*, 1997, pp. 222-30, Vol. 64.

JURIANZ et al., Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2, *Immunopharmacology*, 1999, pp. 209-18, Vol. 42.

KHAZAELI et al., Pharmacokinetics and Immune Response of 131I-Chimeric Mouse/Human B72.3 (Human gamma4) Monoclonal Antibody in Humans, *Cancer Research*, October 15, 1991, pp. 5461-66, Vol. 51.

KING et al., DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma et al., *Nature Medicine*, November 1998, pp. 1281-86, Vol. 4, No. 11.

KINUGASA et al., Expression of membrane cofactor protein (MCP, CD46) in human liver diseases, *British Journal of Cancer*, 1999, pp. 1820-25, Vol. 80, No. 11.

KOHLER et al., Continuous cultures of fused cells secreting antibody of predefined specificity, *Nature*, August 7, 1975, pp. 495-97, Vol. 256.

LISZEWSKI et al., Membrane Cofactor Protein: Importance of N- and O-Glycosylation for Complement Regulatory Function, *The Journal of Immunology*, 1998, pp. 3711-18, Vol. 161.

LISZEWSKI et al., Membrane Cofactor Protein (MCP or CD46): Newest Member of the Regulators of Complement Activation Gene Clusters, *Annu. Rev. Immunol.*, 1991, pp. 431-55, Vol. 9.

MALONEY et al., Newer Treatments for Non-Hodgkin's Lymphoma: Monoclonal Antibodies, *Oncology*, October 1998, pp. 63-76, No. 8.

MATSUDA et al., Organization of the Human Immunoglobulin Heavy-Chain Locus, *Advances in Immunology*, 1996, pp. 1-29, Vol. 62.

MCLAUGHLIN et al., Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program, *Journal of Clinical Oncology*, August 1998, pp. 2825-33, Vol. 16, No. 8.

MENDEZ et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, *Nature Genetics*, February 1997, pp. 146-56, Vol. 15.

MILLER et al., Monoclonal Antibody Therapeutic Trials in Seven Patients with T-Cell Lymphoma, *Blood*, November 1983, pp. 988-95, Vol. 62, No. 5.

MURRAY et al., Expression of Complement Regulatory Proteins -- CD 35, CD 46, CD 55, and CD 59 -- in Benign and Malignant Endometrial Tissue, *Gynecologic Oncology*, 2000, pp. 176-82, Vol. 76.

NANICHE et al., Human Membrane Cofactor Protein (CD46) Acts as a Cellular Receptor for Measles Virus, *Journal of Virology*, October 1993, pp. 6025-32, Vol. 67, No. 10.

OGLESBY et al., Membrane Cofactor Protein (CD46) Protects Cells from Complement-mediated Attack by an Intrinsic Mechanism, J. Exp. Med., June 1992, pp. 1547-51, Vol. 175.

POST et al., Membrane Cofactor Protein of the Complement System: Alternative Splicing of Serine/Threonine/Proline-rich Exons and Cytoplasmic Tails Produces Multiple Isoforms that Correlate with Protein Phenotype, J. Exp. Med., July 1991, pp. 93-102, Vol. 174.

RENNER et al., Tumor Therapy by Immune Recruitment with Bispecific Antibodies, Immunological Reviews, 1995, pp. 179-209, No. 145.

RIECHMANN et al., Reshaping human antibodies for therapy, Nature, March 1988, pp. 323-27, Vol. 332.

RIETHMULLER et al., Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial, Journal of Clinical Oncology, May 1998, pp. 1788-94, Vol. 16, No. 5.

SCHMITT et al., Expression and Regulation by Interferon-gamma of the Membrane-bound Complement Regulators CD46 (MCP), CD55 (DAF) and CD59 in Gastrointestinal Tumours, European Journal of Cancer, 1999, pp. 117-24, Vol. 35, No. 1.

SCHNEIDER-GADICKE et al., Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours, European Journal of Cancer, 1995, pp. 1326-30, Vol. 31A, Nos. 7/8.

SEYA et al., Complement-mediated Tumor Cell Damage Induced by Antibodies against Membrane Cofactor Protein (MCP, DC46), J. Exp. Med., December 1990, pp. 1673-80, Vol. 172.

SEYA et al., Quantitative Analysis of Membrane Cofactor Protein (MCP) of Complement, The Journal of Immunology, July 1, 1990, pp. 238-45, Vol. 145, No. 1.

SHAWLER et al., Human Immune Response to Multiple Injections of Murine Monoclonal IgG, The Journal of Immunology, August 1985, pp. 1530-35, Vol. 135, No. 2.

SIMPSON et al., Expression of the Complement Regulatory Proteins Decay Accelerating Factor (DAF, CD55), Membrane Cofactor Protein (MCP, CD46) and CD59 in the Normal Human Uterine Cervix and in Premalignant and Malignant Cervical Disease, American Journal of Pathology, November 1997, pp. 1455-67, Vol. 151, No. 5.

SLUPSKY et al., The peanut-agglutinin (PNA)-binding surface components of malignant plasma cells, *British Journal of Haematology*, 1993, pp. 567-73, Vol. 83.

STEPHENS et al., Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic response, *Immunology*, 1995, pp. 668-74, Vol. 85.

TERSTAPPEN et al., Identification and Characterization of Plasma Cells in Normal Human Bone Marrow by High-Resolution Flow Cytometry, *Blood*, November 1, 1990, pp. 1739-47, Vol. 76, No. 9.

THORTEINSSON et al., The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues, *APMIS*, 1998, pp. 869-78, Vol. 106.

TRICOT et al., Peripheral Blood Stem Cells Transplants for Multiple Myeloma: Identification of Favorable Variables for Rapid Engraftment in 225 Patients, *Blood*, January 15, 1995, pp. 588-96, Vol. 85, No. 2.

URLAUB et al., Deletion of the Diploid Dihydrofolate Reductase Locus from Cultured Mammalian Cells, *Cell*, June 1983, pp. 405-12, Vol. 33.

VAN DER VUURST DE VRIES et al., Dissecting the human peripheral B-cell compartment with phage display-derived antibodies, *Immunology*, 1999, pp. 55-62, Vol. 98.

VAN DISHOORN et al., Human CD46 Rather Than CD55 is a Key Element in Protection Against Complement Activation In Vitro, *Transplantation Proceedings*, 2000, pp. 916-18, Vol. 32.

VAUGHN et al., Human antibodies by design, *Nature Biotechnology*, June 1998, pp. 535-39, Vol. 16.

VILE et al., Immunotherapy III: Combinatorial molecular immunotherapy -- a synthesis and suggestions, *Cancer and Metastasis Reviews*, 1996, pp. 351-64, Vol. 15.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 2578-4957US
Serial No.: 09/882,621
Filing Date: 6/15/2001
Title: CHIMAERIC PHAGES

Attorney Docket No.: 2578-5016US
Serial No.: 09/909,244
Filing Date: 7/19/2001
Title: A SELECTIVELY-EXPRESSED EPITOPE ON THE HUMAN
CD38 MOLECULE DETECTED BY A PHAGE DISPLAY
LIBRARY-DERIVED HUMAN SCFV ANTIBODY FRAGMENT

Attorney Docket No.: 2578-5420US
Serial No.: 10/184,508
Filing Date: 6/27/2002
Title: USE OF A NATIVE EPITOPE FOR SELECTING EVOLVED
BINDING MEMBERS FROM A LIBRARY OF MUTANTS OF A
PROTEIN CAPABLE OF BINDING TO SAID EPITOPE

Attorney Docket No.: 2578-5420.1US
Serial No.: 10/186,186
Filing Date: 6/28/2002
Title: USE OF A NATIVE EPITOPE FOR SELECTING EVOLVED
BINDING MEMBERS FROM A LIBRARY OF MUTANTS OF A
PROTEIN CAPABLE OF BINDING TO SAID EPITOPE

Attorney Docket No.: 2578-5808US
Serial No.: 10/382,361
Filing Date: 3/5/2003
Title: HEAVY CHAIN LIBRARIES

Attorney Docket No.: 2578-4728.1US
Serial No.: 10/466,466
Filing Date: 7/15/2003
Title: NOVEL FIBRONECTIN EPITOPES AND PROTEINACEOUS
MOLECULES CAPABLE OF BINDING SAID EPITOPES


Attorney Docket No.: 2578-6190US
Serial No.: 10/480,978
Filing Date: 12/15/2003
Title: CHIMAERIC PHAGES

Serial No.: 09/940,386

This Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: February 2, 2004
ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08
Copy of documents cited
Check No. 5712 in the amount of \$180.00

Document in ProLaw



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/940,386
	Filing Date	August 27, 2001
	First Named Inventor	Logtenberg et al.
	Group Art Unit	1645
	Examiner Name	T. Wessendorf
Sheet 1 of 6	Attorney Docket Number	2578-4514 IUS


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ALEXANIAN et al., Drug Therapy, The New England Journal of Medicine, Feb. 17, 1994, pp. 484-89, Vol. 330, No. 7.	
		ATTAL et al., A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma, The New England Journal of Medicine, July 11, 1996, pp. 91-97, Vol. 335, No. 2.	
		BASELGA et al., Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, March 1996, pp. 737-744, Vol. 14, No. 3.	
		BJORKSTRAND et al., Autologous Stem Cell Transplantation in Multiple Myeloma: Results of the European Group for Bone Marrow Transplantation, Stem Cells, 1995, pp. 140-46, Vol. 13.	
		BOCCADORO et al., Diagnosis, Prognosis, and Standard Treatment of Multiple Myeloma, Hematology/Oncology Clinics of North America, February 1997, pp. 111-31, Vol. 11, No. 1.	
		BODEY et al., Genetically Engineered Monoclonal Antibodies for Direct Anti-Neoplastic Treatment and Cancer Cell Specific Delivery of Chemotherapeutic Agents, Current Pharmaceutical Design, 2000, pp. 261-76, Vol. 6.	
		BOEL et al., Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments, Journal of Immunological Methods, 2000, pp. 153-66, Vol. 239.	
		BRUGGEMANN et al., Strategies for expressing human antibody repertoires in transgenic mice, Immunology Today, August 1996, pp. 391-397, Vol. 17, No. 8.	
		BURTON et al., Human Antibodies from Combinatorial Libraries, Advances in Immunology, pp. 191-280, Vol. 57.	
		CUNNINGHAM et al., High-Dose Melphalan and Autologous Bone Marrow Transplantation as Consolidation in Previously Untreated Myeloma, Journal of Clinical Oncology, April 1994, pp. 759-63, Vol. 12, No. 4.	
		CURNOW, Clinical experience with CD64-directed immunotherapy. An overview, Cancer Immunol Immunother, pp. 210-15, Vol. 45.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	09/940,386
Filing Date	August 27, 2001
First Named Inventor	Logtenberg et al.
Group Art Unit	1645
Examiner Name	T. Wessendorf
Attorney Docket Number	2578-4514 IUS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		de KRUIF et al., Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library, Proc. Natl. Acad. Sci., April 1995, pp. 3938-42, Vol. 92.	
		de KRUIF et al., Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions, J. Mol. Biol., 1995, pp. 97-105, Vol. 248.	
		de KRUIF et al., New perspectives on recombinant human antibodies, Trends, October 1996, pp. 453-55, Vol. 17, No. 10.	
		DENNIS et al., Protein glycosylation in development and disease, BioEssays, 1999, pp. 412-21, Vol. 21.	
		DORIG et al., The Human CD46 Molecule Is a Receptor for Measles Virus (Edmonston Strain), Cell, October 22, 1993, pp. 295-305, Vol. 75.	
		ELLIOTT et al., Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis, The Lancet, October 22, 1994, pp. 1125-27, Vol. 344.	
		ENGELMANN et al., Modulated glycosylation of proteoglycans during differentiation of human B lymphocytes, Biochimica et Biophysica Acta, 1995, pp. 6-14, Vol. 1267.	
		FAROOQ et al., Glycosylation of polyclonal and paraprotein IgG in multiple myeloma, Glycoconjugate Journal, 1997, pp. 489-92, Vol. 14.	
		FOOTE et al., Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops, J. Mol. Biol., 1992, pp. 487-99, Vol. 224.	
		GRANZIERO et al., Baculovirus cDNA libraries for expression cloning of genes encoding cell-surface antigens, Journal of Immunological Methods, 1997, pp. 131-309, Vol. 203.	
		HAKIMI et al., Reduced Immunogenicity and Improved Pharmacokinetics of Humanized Anti-Tac in Cynomolgus Monkeys, The Journal of Immunology, August 15, 1991, pp. 1352-59, Vol. 147, No. 4, USA.	
		HARA et al., Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma tears, and seminal fluid in normal subjects, Clin. exp. Immunol. 1992, pp. 490-94, Vol. 89.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	09/940,386
Filing Date	August 27, 2001
First Named Inventor	Logtenberg et al.
Group Art Unit	1645
Examiner Name	T. Wessendorf
Attorney Docket Number	2578-4514 IUS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HAROUSSEAU et al., Autologous Stem Cell Transplantation After First Remission Induction Treatment in Multiple Myeloma: A Report of the French Registry on Autologous Transplantation in Multiple Myeloma, Blood, June 1, 1995, pp. 3077-85, Vol. 85, No. 11.	
		HAVENGA et al., Methotrexate selectable retroviral vectors for Gaucher disease, Gene Therapy, 1998, pp. 1379-88, Vol. 5.	
		HULS et al., A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments, Nature Biotechnology, March 1999, pp. 276-81, Vol. 17.	
		IWATA et al., Diversity of Sites for Measles Virus Binding and for Inactivation of Complement C3b and C4b on Membrane Cofactor Protein CD46*, The Journal of Biological Chemistry, 1995, pp. 15148-52, Vol. 270, No. 25.	
		JONES et al., Replacing the complementarity--determining regions in a human antibody with those from a mouse, Nature, May 1986, pp. 522-525, Vol. 321.	
		JUHL et al., Frequent Expression of Complement Resistance Factors CD46, CD55, and CD59 on Gastrointestinal Cancer Cells Limits the Therapeutic Potential of Monoclonal Antibody 17-1A, Journal of Surgical Oncology, 1997, pp. 222-30, Vol. 64.	
		JURIANZ et al., Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2, Immunopharmacology, 1999, pp. 209-18, Vol. 42.	
		KHAZAELI et al., Pharmacokinetics and Immune Response of 131I-Chimeric Mouse/Human B72.3 (Human gamma4) Monoclonal Antibody in Humans, Cancer Research, October 15, 1991, pp. 5461-66, Vol. 51.	
		KING et al., DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma et al., Nature Medicine, November 1998, pp. 1281-86, Vol. 4, No. 11.	
		KINUGASA et al., Expression of membrane cofactor protein (MCP, CD46) in human liver diseases, British Journal of Cancer, 1999, pp. 1820-25, Vol. 80, No. 11.	
		KOHLER et al., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, August 7, 1975, pp. 495-97, Vol. 256.	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B(10-01)



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/940,386
		Filing Date	August 27, 2001
		First Named Inventor	Logtenberg et al.
		Group Art Unit	1645
		Examiner Name	T. Wessendorf
Sheet 4 of 6	Attorney Docket Number	2578-4514 IUS	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LISZEWSKI et al., Membrane Cofactor Protein: Importance of N- and O-Glycosylation for Complement Regulatory Function, The Journal of Immunology, 1998, pp. 3711-18, Vol. 161.	
		LISZEWSKI et al., Membrane Cofactor Protein (MCP or CD46): Newest Member of the Regulators of Complement Activation Gene Clusters, Annu. Rev. Immunol., 1991, pp. 431-55, Vol. 9.	
		MALONEY et al., Newer Treatments for Non-Hodgkin's Lymphoma: Monoclonal Antibodies, Oncology, October 1998, pp. 63-76, No. 8.	
		MATSUDA et al., Organization of the Human Immunoglobulin Heavy-Chain Locus, Advances in Immunology, 1996, pp. 1-29, Vol. 62.	
		MCLAUGHLIN et al., Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program, Journal of Clinical Oncology, August 1998, pp. 2825-33, Vol. 16, No. 8.	
		MENDEZ et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nature Genetics, February 1997, pp. 146-56, Vol. 15.	
		MILLER et al., Monoclonal Antibody Therapeutic Trials in Seven Patients with T-Cell Lymphoma, Blood, November 1983, pp. 988-95, Vol. 62, No. 5.	
		MURRAY et al., Expression of Complement Regulatory Proteins -- CD 35, CD 46, CD 55, and CD 59 -- in Benign and Malignant Endometrial Tissue, Gynecologic Oncology, 2000, pp. 176-82, Vol. 76.	
		NANICHE et al., Human Membrane Cofactor Protein (CD46) Acts as a Cellular Receptor for Measles Virus, Journal of Virology, October 1993, pp. 6025-32, Vol. 67, No. 10.	
		OGLESBY et al., Membrane Cofactor Protein (CD46) Protects Cells from Complement-mediated Attack by an Intrinsic Mechanism, J. Exp. Med., June 1992, pp. 1547-51, Vol. 175.	
		POST et al., Membrane Cofactor Protein of the Complement System: Alternative Splicing of Serine/Threonine/Proline-rich Exons and Cytoplasmic Tails Produces Multiple Isoforms that Correlate with Protein Phenotype, J. Exp. Med., July 1991, pp. 93-102, Vol. 174.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

6

Complete if Known

Application Number	09/940,386
Filing Date	August 27, 2001
First Named Inventor	Logtenberg et al.
Group Art Unit	1645
Examiner Name	T. Wessendorf
Attorney Docket Number	2578-4514 IUS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		RENNER et al., Tumor Therapy by Immune Recruitment with Bispecific Antibodies, Immunological Reviews, 1995, pp. 179-209, No. 145.	
		RIECHMANN et al., Reshaping human antibodies for therapy, Nature, March 1988, pp. 323-27, Vol. 332.	
		RIETHMULLER et al., Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial, Journal of Clinical Oncology, May 1998, pp. 1788-94, Vol. 16, No. 5.	
		SCHMITT et al., Expression and Regulation by Interferon-gamma of the Membrane-bound Complement Regulators CD46 (MCP), CD55 (DAF) and CD59 in Gastrointestinal Tumours, European Journal of Cancer, 1999, pp. 117-24, Vol. 35, No. 1.	
		SCHNEIDER-GADICKE et al., Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours, European Journal of Cancer, 1995, pp. 1326-30, Vol. 31A, Nos. 7/8.	
		SEYA et al., Complement-mediated Tumor Cell Damage Induced by Antibodies against Membrane Cofactor Protein (MCP, DC46), J. Exp. Med., December 1990, pp. 1673-80, Vol. 172.	
		SEYA et al., Quantitative Analysis of Membrane Cofactor Protein (MCP) of Complement, The Journal of Immunology, July 1, 1990, pp. 238-45, Vol. 145, No. 1.	
		SHAWLER et al., Human Immune Response to Multiple Injections of Murine Monoclonal IgG, The Journal of Immunology, August 1985, pp. 1530-35, Vol. 135, No. 2.	
		SIMPSON et al., Expression of the Complement Regulatory Proteins Decay Accelerating Factor (DAF, CD55), Membrane Cofactor Protein (MCP, CD46) and CD59 in the Normal Human Uterine Cervix and in Premalignant and Malignant Cervical Disease, American Journal of Pathology, November 1997, pp. 1455-67, Vol. 151, No. 5.	
		SLUPSKY et al., The peanut-agglutinin (PNA)-binding surface components of malignant plasma cells, British Journal of Haematology, 1993, pp. 567-73, Vol. 83.	
		STEPHENS et al., Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic response, Immunology, 1995, pp. 668-74, Vol. 85.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 6

Complete if Known

Application Number	09/940,386
Filing Date	August 27, 2001
First Named Inventor	Logtenberg et al.
Group Art Unit	1645
Examiner Name	T. Wessendorf
Attorney Docket Number	2578-4514 IJS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TERSTAPPEN et al., Identification and Characterization of Plasma Cells in Normal Human Bone Marrow by High-Resolution Flow Cytometry, Blood, November 1, 1990, pp. 1739-47, Vol. 76, No. 9.	
		THORTEINSSON et al., The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues, APMIS, 1998, pp. 869-78, Vol. 106.	
		TRICOT et al., Peripheral Blood Stem Cells Transplants for Multiple Myeloma: Identification of Favorable Variables for Rapid Engraftment in 225 Patients, Blood, January 15, 1995, pp. 588-96, Vol. 85, No. 2.	
		URLAUB et al., Deletion of the Diploid Dihydrofolate Reductase Locus from Cultured Mammalian Cells, Cell, June 1983, pp. 405-12, Vol. 33.	
		VAN DER VUURST DE VRIES et al., Dissecting the human peripheral B-cell compartment with phage display-derived antibodies, Immunology, 1999, pp. 55-62, Vol. 98.	
		VAN DISHOORN et al., Human CD46 Rather Than CD55 is a Key Element in Protection Against Complement Activation In Vitro, Transplantation Proceedings, 2000, pp. 916-18, Vol. 32.	
		VAUGHN et al., Human antibodies by design, Nature Biotechnology, June 1998, pp. 535-39, Vol. 16.	
		VILE et al., Immunotherapy III: Combinatorial molecular immunotherapy -- a synthesis and suggestions, Cancer and Metastasis Reviews, 1996, pp. 351-64, Vol. 15.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.